Prostate cancer (PC) is the second most commonly occurring cancer in men. Conventional
chemotherapy has wide variety of disadvantages such as high systemic toxicity and low …

Prostate cancer (PCa) is the most prevalent cancer among men in the United States and
remains the second-leading cause of cancer mortality in men. Paclitaxel (PTX) is the first line …

Prostate-specific membrane antigen (PSMA) provides an attractive target for the
development of targeted chemotherapeutics for prostate cancer. We have designed and …

Targeting therapy is a concept that has gained significant importance in recent years,
especially in oncology. The severe dose-limiting side effects of chemotherapy necessitate …

Most patients with advanced prostate cancer (PCa) will develop metastatic castration-
resistant prostate cancer (mCRPC) after androgen deprivation therapy, at this time the tumor …

Prostate cancer is one of the most commonly diagnosed men's cancers and remains one of
the leading causes of cancer death. The development of approaches to the treatment of this …

Active targeting to cancer involves exploiting specific interactions between receptors on the
surface of cancer cells and targeting moieties conjugated to the surface of vectors such that …

Prostate cancer is the second most common cancer among men. We designed and
synthesized new ligands targeting prostate-specific membrane antigen and suitable for …

177Lu-labeled small-molecule prostate-specific membrane antigen (PSMA) targeted tracers
are therapeutic agents for metastatic castration-resistant prostate cancer. Optimizing …

Simple Summary Currently, there is no effective treatment that can cure metastatic prostate
cancer. Various pros-tate specific membrane antigen (PSMA)-targeted radioimaging and …